The in-vitro activity of trovafloxacin and nine other antimicrobials was determined for 413 non copy anaerobic clinical isolates. Trovafloxacin was the most active quinolone tested with an MIG» of 0.5 mg/L against Gram-positive cocci (n = 75); MIG» of 4 mg/L against Gram-positive bacilli (n = 151); MIG» of 0.5 mg/L for Gram-negative cocci (n = 12) and MIC™ of 1 mg/L for Gram-negative bacilli (n = 175). Overall the MIGw of trovafloxacin was 1 mg/L which was equivalent to co-amoxiclav and one dilution higher than that of imipenem. The other seven comparators, including clindamycin and metronidazole, had higher MIGw values than trovafloxacin. Trovafloxacin is likely to have clinically useful activity against anaerobes from human infection.
Introduction
Fluoroquinolones, such as ciprofloxacin or ofloxacin, are a widely used group of antimicrobial agents because of their relatively non toxic safety profile, availability in oral or parenteral formulations and antimicrobial activity against a wide number of Gram-negative aerobic species including Pseudomonas aeruginosa. However existing quinolones have incomplete antibacterial spectra, particularly having poor activity against Gram-positive aerobes or anaerobes. Hence they are often given in combination with specific anti-Gram-positive agents, such as isoxazolyl penicillins or glycopeptides, or anti-anaerobic agents such as metronidazole. Recently a number of developmental quinolones, including sparfloxacin, clinafloxacin (CI960), WIN 57273, Bay y 3118 and trovafloxacin (Endermann & Brenm, 1992; Goldstein & Citron, 1992; Spangler, Jacobs & Appelbaum, 1994; Wexler el al. 1994) , have been shown to have activity against anaerobic bacteria. As such agents retain excellent in-vitro activity against Gram-negative species it is possible these antibacterials could be employed as monotherapy in mixed aerobic and anaerobic infections. In this study we evaluated trovafloxacin and nine comparators against 413 anaerobic strains isolated from human sources in the United Kingdom. 
Materials and methods
Two hundred and twenty six Gram-positive and 187 Gram-negative anaerobes were tested. One hundred and fifty three were clinical isolates from the collection of bacteria held at Southmead Hospital. Other isolates were provided by the Bristol Dental Hospital (n = 79); the PHLS Anaerobe Reference Unit, Cardiff {n = 105), Zeneca Pharma (n = 8) and Dr David Murdoch of this Department {n = 68). Anaerobes were identified by conventional methods, (Phillips, 1976; Murdoch & Mitchelmore, 1991 Amoxycillin plus clavulanate were used in a 4:1 ratio, and piperacillin plus tazobactam in a 8:1 ratio.
Agar dilution MICs were performed on Wilkins Chalgren Agar (CM619 Unipath) supplemented with 5% lysed horse blood. The antibiotics were incorporated into the medium in a log 2 dilution series from 0.008-128 mg/L. Inocula were prepared by diluting to McFarland 0.5 equivalent in saline, resulting in approximately lO'cfu per spot when applied by a Denley multi-point inoculator. The plates were incubated anaerobically in an atmosphere of 80% N 2 , 10% H 2 , 10% CO 2 at 37°C for 40 h in a Wise Anaerobic Workstation (Don Whitley Scientific) and were read by eye in comparison with an antibiotic-free control plate. The MIC was defined as the lowest concentration of drug to inhibit macroscopically visible colonies.
Results and discussion
The in-vitro activity of trovafloxacin and the nine other antimicrobial agents is summarised in terms of MIC range, MIC^ and MIG» in mg/L for each species or group of anaerobes (Table I) . These parameters were also determined for all the Gram-positive cocci (n = 75), Gram-positive bacilli (n = 151), Gram-negative cocci (n = 12) and Gram-negative bacilli (n = 175) grouped together as well as for the total number of strains tested (« = 413).
Trovafloxacin had an MIC50 of 0.25 mg/L and an MIC90 of 1 mg/L for all the strains tested (n = 413). It was at least four times more active overall than the other quinolones tested, that is, ciprofloxacin and ofloxacin. The MIG» of trovafloxacin was less than or equal to that of all the other agents with the exception of imipenem which had an MIC*, of 0.5 mg/L.
Trovafloxacin was more active than ciprofloxacin and ofloxacin against Gram-positive cocci, Gram-positive bacilli and Gram-negative bacilli (Table I) . However, while Veillonella spp. were susceptible to all three quinolones tested, they showed greatest sensitivity to ciprofloxacin.
Trovafloxacin had broadly similar activity to the /Mactams tested against Gram-positive cocci, but was not as active as metronidazole. In contrast, trovafloxacin was more active than metronidazole against Gram-positive bacilli and had similar activity to the /f-lactams. Actinomyces spp., Lactobacillus spp., and Propionibacterium acnes were susceptible to trovafloxacin but resistant to metronidazole.
Actinomyces israelii had the highest MIC50 of trovafloxacin (MIC50 = 8 mg/L) and Actinomyces spp., Prevotella buccae, Prevotella spp. and P. acnes all had MIC50 of 1 mg/L. For the other 26 species or groups analysed the MICjo was less than or equal to 0.5 mg/L.
The activity of trovafloxacin against some more rarely isolated anaerobe strains is shown on Table II. All were inhibited by trovafloxacin at a concentration of 1 mg/L or less.
Trovafloxacin (CP99219-mesylate salt) is well absorbed with a bioavailability of around 90% in man and an intravenous dose of 300 mg/day of CP 116, 517, the iv prodrug of trovafloxacin, produces maximum serum trovafloxicin concentrations of 2.9 mg/L on the first day of administration and concentrations of 3.3 mg/L on day 17 (Pfizer, data on file). The 413 anaerobic strains had an MIG» of 1 mg/L which agrees closely with that given by Spangler et al. (1994) , who tested 489 strains and also found the MIC« to be 1 mg/L. Trovafloxacin may then have useful activity in the therapy of human anaerobic infections. Other factors such as the detailed pharmacokinetics of trovafloxacin bactericidal activity, inhibitory activity against aerobes, inoculum effect, post-antibiotic effect and performance in in-vitro models should be taken into account when deciding dosages and frequency of administration for clinical trials.
